Morphological and physicochemical evaluation of the propranolol HCl–Eudragit^® RS100 electrosprayed nanoformulations

Figures & data

Figure 1. Schematic view of electrospraying apparatus.

Table 1. Polymer: drug ratios of the prepared samples.

Formulation	Drug:polymer ratio	Solution concentration (w/v)
F1	1:5	10%
F2	1:5	15%
F3	1:5	20%
F4	1:10	10%
F5	1:10	15%
F6	1:10	20%

Figure 2. FE-SEM images of Prop. HCl-eudragit^® RS100 electrosprayed formulations with the polymer:drug ratios and solution concentrations of (a) 5:1–10% (w/v), (b) 5:1 – 15% (w/v), (c) 5:1 – 20% (w/v), (d) 10:1 – 10% (w/v), (e) 10:1 – 15% (w/v) and (f) 10:1 – 20% (w/v).

Figure 3. DSC thermograms of the pure Prop. HCl; eudragit^® RS100; PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).

Figure 4. PXRD patterns of Prop. (Pure drug), Eudragit^® RS100, PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).

Figure 5. FT-IR spectrum of Prop. (Pure drug), Eudragit^® RS100, PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).

Figure 6. The release behaviour of the pure drug (Prop. HCl), PM (physical mixtures) and the electrosprayed nanoformulations. Drug:polymer ratios were indicated by 1:5 and 1:10. Solution concentrations were denoted by 10%, 15% and 20%. Each data show mean ± SD (n = 3).